ArticleJournal of radiation research2026
Utility of 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in assessing treatment response after chemoradiotherapy for cervical cancer.
Article in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cervical cancer is the fourth most common malignancy globally. As many cases are locally advanced, early prediction of local recurrence, which often occurs within 2 years of chemoradiotherapy (CCRT), is crucial. The National Comprehensive Cancer Network Guidelines recommend post-treatment 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) for response assessment, but this is not standard in Japan. We aimed to investigate the utility of 18F-FDG-PET/CT in assessing primary tumor response after CCRT for cervical cancer. Seventy-three patients with cervical cancer who received curative CCRT and underwent pre- and post-treatment magnetic resonance imaging and 18F-FDG-PET/CT were analyzed. We collected PET metrics (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and classified the response. Receiver operating characteristic (ROC) curve analysis was performed on the post-treatment PET data. Univariate analysis was performed to determine the prognostic factors for local control. ROC curve analysis yielded high negative predictive values for local recurrence of post-treatment MTV, SUVmax and TLG. Univariate analysis showed significant differences in local control for post-treatment MTV, SUVmax, TLG and PET Response Criteria in Solid Tumors, but not for Response Evaluation Criteria in Solid Tumors (RECIST). Functional assessment using 18F-FDG-PET/CT after CCRT for cervical cancer is useful for complementing conventional morphological evaluation and improving the accuracy of response assessment.
Indexed as
Identifiers
42560332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.